{"id":22028,"date":"2022-08-01T09:36:56","date_gmt":"2022-08-01T07:36:56","guid":{"rendered":"https:\/\/idibell.cat\/?p=22028"},"modified":"2022-08-01T09:37:58","modified_gmt":"2022-08-01T07:37:58","slug":"un-estudi-de-lidibell-i-lidibgi-avalua-leficacia-dun-anti-tumoral-en-la-lluita-contra-lobesitat","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2022\/08\/un-estudi-de-lidibell-i-lidibgi-avalua-leficacia-dun-anti-tumoral-en-la-lluita-contra-lobesitat\/","title":{"rendered":"Un estudi de l\u2019IDIBELL i l&#8217;IDIBGI avalua l&#8217;efic\u00e0cia d\u2019un anti-tumoral en la lluita contra l&#8217;obesitat"},"content":{"rendered":"<p>L\u2019obesitat \u00e9s un problema de salut d\u2019abast mundial. Una de les estrat\u00e8gies terap\u00e8utiques m\u00e9s recurrents \u00e9s la que proposa frenar l\u2019expansi\u00f3 del teixit adip\u00f3s (el greix corporal) en el moment en que les c\u00e8l\u00b7lules mare precursores proliferen i es transformen en c\u00e8l\u00b7lules adiposes. La prote\u00efna S6K1 t\u00e9 un paper indispensable en aquest proc\u00e9s.<\/p>\n<p>Un estudi liderat per l\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) i l\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Girona (IDIBGI) ha avaluat els efectes d\u2019un f\u00e0rmac que inhibeix l\u2019activitat de la prote\u00efna S6K1 per valorar el seu potencial terap\u00e8utic en el tractament de l\u2019obesitat. Els resultats, publicats a la revista cient\u00edfica <a href=\"https:\/\/insight.jci.org\/articles\/view\/150461?utm_content=buffer22e61&amp;utm_medium=social&amp;utm_source=twitter.com&amp;utm_campaign=buffer\"><em>JCI Insight<\/em><\/a>, demostren que els ratolins alimentats amb una dieta molt alta en greixos i tractats amb aquest agent anti-tumoral, el tosilat <strong>LY3584703<\/strong>, presentaven, en comparaci\u00f3 amb els ratolins que no van ser tractats amb el f\u00e0rmac, un menor pes corporal, menys quantitat de greix acumulat i adip\u00f2cits (c\u00e8l\u00b7lula preferent dels dip\u00f2sits de greix) m\u00e9s petits.<\/p>\n<p>A m\u00e9s, es va observar l\u2019efecte benefici\u00f3s en altres trastorns t\u00edpicament associats a l\u2019obesitat, com el fetge gras o la dislip\u00e8mia (l\u2019exc\u00e9s de colesterol o triglic\u00e8rids a la sang): \u201c<em>un altre efecte molt interessant \u00e9s que el f\u00e0rmac aconsegueix mitigar l\u2019acumulaci\u00f3 de greix al fetge, i tamb\u00e9 que redueix la hipertrigliceridemia, l\u2019exc\u00e9s de triglic\u00e8rids circulant a la sang<\/em>\u201d, afirma el <strong>Dr. Francisco Jos\u00e9 Ortega<\/strong>, l\u2019investigador principal del grup de recerca en Nutrici\u00f3, Eumetabolisme i Salut de l\u2019IDIBGI i el CIBER de la Fisiopatologia de l\u2019Obesitat i la Nutrici\u00f3 (CIBEROBN) que ha liderat aquest treball.<\/p>\n<p>\u201c<em>Aquests resultats fan un apropament conven\u00e7ut a la cl\u00ednica, i demostren que l\u2019administraci\u00f3 oral d\u2019un compost dirigit espec\u00edficament contra la prote\u00efna S6K1 pot millorar el fenotip ob\u00e8s i les comorbiditats t\u00edpicament associades a aquesta condici\u00f3<\/em>\u201d, conclou el <strong>Dr. Ortega<\/strong>.<\/p>\n<p>Aquest estudi deriva de la l\u00ednia de recerca desenvolupada fa vint anys per la <strong>Dra. Sara Kozma<\/strong> i el <strong>Dr. George Thomas<\/strong>, tots dos investigadors de l\u2019IDIBELL. Aquests autors demostraven que els ratolins que no tenen el gen responsable de la prote\u00efna S6K1 poden arribar a menjar molt sense engreixar-se ni patir problemes metab\u00f2lics.<\/p>\n<p>A m\u00e9s de l\u2019IDIBELL i l\u2019IDIBGI, han participat en aquest estudi investigadors de la Universitat de Cardiff i la Universitat de Newcastle (Regne Unit), l\u2019Hospital Universitari de Regensburg (Alemanya), i l\u2019Institut per la Recerca M\u00e8dica de la Fundaci\u00f3 Minerva (Finl\u00e0ndia), i ha estat parcialment finan\u00e7at per la Fundaci\u00f3 La Marat\u00f3 de TV3 de l\u2019any 2016.<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><em>L\u2019Institut d&#8217;Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l&#8217;Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l&#8217;Institut Catal\u00e0 de la Salut, l&#8217;Institut Catal\u00e0 d&#8217;Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n<p><em>L\u2019IDIBELL \u00e9s membre del Campus d&#8217;Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L&#8217;any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>El f\u00e0rmac inhibeix la prote\u00efna S6K1, que \u00e9s indispensable pel desenvolupament de noves c\u00e8l\u00b7lules adiposes, responsables del creixement desproporcionat dels dip\u00f2sits de greix en persones obeses.<\/p>\n","protected":false},"author":8,"featured_media":22029,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[332,365,408,447],"tags":[],"class_list":["post-22028","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-cancer-ginecologic","category-metabolisme-del-cancer","category-p-de-mecanismes-molelculars-i-terapia-experimental-en-oncologia-oncobell"],"publishpress_future_action":{"enabled":false,"date":"2024-12-25 13:17:44","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/22028","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=22028"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/22028\/revisions"}],"predecessor-version":[{"id":22030,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/22028\/revisions\/22030"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/22029"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=22028"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=22028"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=22028"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}